154 related articles for article (PubMed ID: 16778104)
1. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma.
Piekarz RL; Frye AR; Wright JJ; Steinberg SM; Liewehr DJ; Rosing DR; Sachdev V; Fojo T; Bates SE
Clin Cancer Res; 2006 Jun; 12(12):3762-73. PubMed ID: 16778104
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
[TBL] [Abstract][Full Text] [Related]
3. Nursing Roles in Cardiac Safety: Romidepsin in Patients With T-Cell Lymphoma.
Hronek J; Reed M
Oncol Nurs Forum; 2016 Mar; 43(2):227-34. PubMed ID: 26906133
[TBL] [Abstract][Full Text] [Related]
4. Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma.
Kim M; Thompson LA; Wenger SD; O'Bryant CL
Ann Pharmacother; 2012 Oct; 46(10):1340-8. PubMed ID: 22968522
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.
Byrd JC; Marcucci G; Parthun MR; Xiao JJ; Klisovic RB; Moran M; Lin TS; Liu S; Sklenar AR; Davis ME; Lucas DM; Fischer B; Shank R; Tejaswi SL; Binkley P; Wright J; Chan KK; Grever MR
Blood; 2005 Feb; 105(3):959-67. PubMed ID: 15466934
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors.
Shah MH; Binkley P; Chan K; Xiao J; Arbogast D; Collamore M; Farra Y; Young D; Grever M
Clin Cancer Res; 2006 Jul; 12(13):3997-4003. PubMed ID: 16818698
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of depsipeptide in refractory metastatic renal cell cancer.
Stadler WM; Margolin K; Ferber S; McCulloch W; Thompson JA
Clin Genitourin Cancer; 2006 Jun; 5(1):57-60. PubMed ID: 16859580
[TBL] [Abstract][Full Text] [Related]
8. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.
Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Borchmann P; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan S; Shustov A; Nichols J; Carroll S; Balser J; Balser B; Horwitz S
J Clin Oncol; 2012 Feb; 30(6):631-6. PubMed ID: 22271479
[TBL] [Abstract][Full Text] [Related]
9. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
Konstantinopoulos PA; Vandoros GP; Papavassiliou AG
Cancer Chemother Pharmacol; 2006 Nov; 58(5):711-5. PubMed ID: 16435156
[TBL] [Abstract][Full Text] [Related]
10. Electrocardiogram mimics of acute ST-segment elevation myocardial infarction: insights from cardiac magnetic resonance imaging in patients with tako-tsubo (stress) cardiomyopathy.
Sharkey SW
J Electrocardiol; 2008; 41(6):621-5. PubMed ID: 18790504
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.
; Fouladi M; Furman WL; Chin T; Freeman BB; Dudkin L; Stewart CF; Krailo MD; Speights R; Ingle AM; Houghton PJ; Wright J; Adamson PC; Blaney SM
J Clin Oncol; 2006 Aug; 24(22):3678-85. PubMed ID: 16877737
[TBL] [Abstract][Full Text] [Related]
12. Depsipeptide induces cell death in Hodgkin lymphoma-derived cell lines.
Hartlapp I; Pallasch C; Weibert G; Kemkers A; Hummel M; Re D
Leuk Res; 2009 Jul; 33(7):929-36. PubMed ID: 19233470
[TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular responses in lung cancer patients receiving Romidepsin.
Schrump DS; Fischette MR; Nguyen DM; Zhao M; Li X; Kunst TF; Hancox A; Hong JA; Chen GA; Kruchin E; Wright JJ; Rosing DR; Sparreboom A; Figg WD; Steinberg SM
Clin Cancer Res; 2008 Jan; 14(1):188-98. PubMed ID: 18172270
[TBL] [Abstract][Full Text] [Related]
14. Modulation of ventricular repolarization in patients with transient left ventricular apical ballooning: a case control study.
Bonnemeier H; Ortak J; Bode F; Kurowski V; Reppel M; Weitz G; Barantke M; Schunkert H; Wiegand UK
J Cardiovasc Electrophysiol; 2006 Dec; 17(12):1340-7. PubMed ID: 17096660
[TBL] [Abstract][Full Text] [Related]
15. Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).
Sutheesophon K; Nishimura N; Kobayashi Y; Furukawa Y; Kawano M; Itoh K; Kano Y; Ishii H; Furukawa Y
J Cell Physiol; 2005 May; 203(2):387-97. PubMed ID: 15515013
[TBL] [Abstract][Full Text] [Related]
16. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies.
Auner HW; Tinchon C; Linkesch W; Tiran A; Quehenberger F; Link H; Sill H
Ann Hematol; 2003 Apr; 82(4):218-22. PubMed ID: 12679885
[TBL] [Abstract][Full Text] [Related]
17. Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin.
Sager PT; Balser B; Wolfson J; Nichols J; Pilot R; Jones S; Burris HA
Cancer Med; 2015 Aug; 4(8):1178-85. PubMed ID: 25914207
[TBL] [Abstract][Full Text] [Related]
18. Depsipeptide a histone deacetlyase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549).
Vinodhkumar R; Song YS; Ravikumar V; Ramakrishnan G; Devaki T
Chem Biol Interact; 2007 Feb; 165(3):220-9. PubMed ID: 17240363
[TBL] [Abstract][Full Text] [Related]
19. Depsipeptide and roxithromycin induce apoptosis of lymphoma cells by blocking extracellular signal-regulated kinase activation.
Morimura S; Sugaya M; Kai H; Miyagaki T; Asano Y; Tada Y; Kadono T; Murakami T; Sato S
J Dermatol; 2014 Jan; 41(1):57-62. PubMed ID: 24438145
[TBL] [Abstract][Full Text] [Related]
20. Romidepsin in the treatment of T-cell lymphoma: profile report.
Yang LP
BioDrugs; 2011 Dec; 25(6):393-5. PubMed ID: 22050341
[No Abstract] [Full Text] [Related]
[Next] [New Search]
